Cargando…

Carnitine metabolites and cognitive improvement in patients with schizophrenia treated with olanzapine: a prospective longitudinal study

Objective: Cognitive impairment is one of the core symptoms of schizophrenia, which is stable and lifelong. L-carnitine has been shown to improve cognitive function and decrease the rate of cognitive deterioration in patients with Alzheimer’s disease. However, it remains unclear regarding the role o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Lei, Liu, Hua, Wang, Wenjuan, Wang, Youping, Xiu, Meihong, Li, Shuyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470116/ https://www.ncbi.nlm.nih.gov/pubmed/37663259 http://dx.doi.org/10.3389/fphar.2023.1255501

Ejemplares similares

Kynurenine pathway metabolites and therapeutic response to olanzapine in female patients with schizophrenia: A longitudinal study
por: Guan, Xiaoni, et al.
Publicado: (2022)

Plasma Lysophosphatidylcholine and Lysophosphatidylethanolamine Levels Were Associated With the Therapeutic Response to Olanzapine in Female Antipsychotics-naïve First-episode Patients With Schizophrenia
por: Liu, Jiahong, et al.
Publicado: (2021)

Effects of low-dose combined olanzapine and sertraline on negative and depressive symptoms in treatment-resistant outpatients with acute exacerbated schizophrenia
por: Lang, Xiaoe, et al.
Publicado: (2023)

Baseline BMI is associated with clinical symptom improvements in first-episode schizophrenia: a longitudinal study
por: Chen, Xiaofang, et al.
Publicado: (2023)

Genetic Association of Olanzapine Treatment Response in Han Chinese Schizophrenia Patients
por: Zhou, Wei, et al.
Publicado: (2019)

The Relationships Between Hyperprolactinemia, Metabolic Disturbance, and Sexual Dysfunction in Patients With Schizophrenia Under Olanzapine Treatment
por: Wu, Tzu-Hua, et al.
Publicado: (2021)

Increased Appetite Plays a Key Role in Olanzapine-Induced Weight Gain in First-Episode Schizophrenia Patients
por: Huang, Jing, et al.
Publicado: (2020)

Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia
por: Lu, Mong-Liang, et al.
Publicado: (2016)

Corrigendum: Increased Appetite Plays a Key Role in Olanzapine-Induced Weight Gain in First-Episode Schizophrenia Patients
por: Huang, Jing, et al.
Publicado: (2020)

Olanzapine-Induced Hyperprolactinemia: Two Case Reports
por: Barata, Pedro Cabral, et al.
Publicado: (2019)

Vitamin D supplementation is effective for olanzapine-induced dyslipidemia
por: Zhou, Zijian, et al.
Publicado: (2023)

Paroxetine combined with olanzapine in the treatment of schizophrenia
por: Wang, Ning, et al.
Publicado: (2020)

Olanzapine‐associated dose‐dependent alterations for weight and metabolic parameters in a prospective cohort
por: Schoretsanitis, Georgios, et al.
Publicado: (2022)

Glucose metabolism, hippocampal subfields and cognition in first-episode and never-treated schizophrenia
por: Xiu, Meihong, et al.
Publicado: (2023)

Sex-Specific Association between Antioxidant Defense System and Therapeutic Response to Risperidone in Schizophrenia: A Prospective Longitudinal Study
por: Liu, Haixia, et al.
Publicado: (2022)

Carnitine Palmitoyltransferase System: A New Target for Anti-Inflammatory and Anticancer Therapy?
por: Wang, Muyun, et al.
Publicado: (2021)

Sexual dysfunction in male schizophrenia remitted patients treated with risperidone and olanzapine
Publicado: (2022)

Characterizing acyl-carnitine biosignatures for schizophrenia: a longitudinal pre- and post-treatment study
por: Cao, Bing, et al.
Publicado: (2019)

Antioxidant Enzymes and Weight Gain in Drug-naive First-episode Schizophrenia Patients Treated with Risperidone for 12 Weeks: A Prospective Longitudinal Study
por: Liu, Haixia, et al.
Publicado: (2022)

Physiologically Based Pharmacokinetic Modeling in Pregnant Women Suggests Minor Decrease in Maternal Exposure to Olanzapine
por: Zheng, Liang, et al.
Publicado: (2022)

The Role of the Carnitine/Organic Cation Transporter Novel 2 in the Clinical Outcome of Patients With Locally Advanced Esophageal Carcinoma Treated With Oxaliplatin
por: Sun, Dongfeng, et al.
Publicado: (2021)

Relationship Between Plasma Olanzapine and N-Desmethyl-Olanzapine Concentration and Metabolic Parameters in Patients With Schizophrenia
por: An, Huimei, et al.
Publicado: (2022)

Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone
por: Soria-Chacartegui, Paula, et al.
Publicado: (2021)

Effect of olanzapine combined with risperidone in the treatment of schizophrenia and its influence on cognitive function
por: Yang, Lujie, et al.
Publicado: (2021)

Reduced activity and connectivity of left amygdala in patients with schizophrenia treated with clozapine or olanzapine
por: Mier, Daniela, et al.
Publicado: (2018)

Empagliflozin Effectively Attenuates Olanzapine-Induced Body Weight Gain in Female Wistar Rats
por: Ashraf, Ghulam Md, et al.
Publicado: (2021)

Superoxide Dismutase, BDNF, and Cognitive Improvement in Drug-Naive First-Episode Patients With Schizophrenia: A 12-Week Longitudinal Study
por: Wu, Zhiwei, et al.
Publicado: (2021)

GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells
por: Filatova, Elena, et al.
Publicado: (2017)

Olanzapine-induced lipid disturbances: A potential mechanism through the gut microbiota-brain axis
por: Zhu, Zhenyu, et al.
Publicado: (2022)

Arginine and Carnitine Metabolites Are Altered in Diabetic Retinopathy
por: Sumarriva, Katherine, et al.
Publicado: (2019)

Serotonin and dopamine receptors in motivational and cognitive disturbances of schizophrenia
por: Sumiyoshi, Tomiki, et al.
Publicado: (2014)

L-carnitine attenuated hyperuricemia-associated left ventricular remodeling through ameliorating cardiomyocytic lipid deposition
por: Yang, Yang, et al.
Publicado: (2023)

Electrophysiological Abnormalities in VLCAD Deficient hiPSC-Cardiomyocytes Do not Improve with Carnitine Supplementation
por: Verkerk, Arie O., et al.
Publicado: (2021)

Enhancing endogenous levels of GLP1 dampens acute olanzapine induced perturbations in lipid and glucose metabolism
por: Medak, Kyle D., et al.
Publicado: (2023)

Effects of olanzapine on anhedonia in schizophrenia: mediated by complement factor H
por: Zhang, Yi, et al.
Publicado: (2023)

Risk factors, clinical correlates, and social functions of Chinese schizophrenia patients with drug-induced parkinsonism: A cross-sectional analysis of a multicenter, observational, real-world, prospective cohort study
por: Weng, Jiajun, et al.
Publicado: (2023)

L-carnitine prevents lenvatinib-induced muscle toxicity without impairment of the anti-angiogenic efficacy
por: Jing, Zheng, et al.
Publicado: (2023)

Alterations in sorting and secretion of hepatic apoA5 induce hypertriglyceridemia due to short-term use of olanzapine
por: Huang, Piao-Piao, et al.
Publicado: (2022)

Metformin ameliorates olanzapine-induced obesity and glucose intolerance by regulating hypothalamic inflammation and microglial activation in female mice
por: Suh, Sang Bum, et al.
Publicado: (2022)

Effect of Olanzapine on Clinical and Polysomnography Profiles in Patients with Schizophrenia
por: Katshu, Mohammad Zia Ul Haq, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_pq3mi2a6j9vv55ju84t5m8soba